Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perinatal outcomes with active versus expectant management in term pre-labor rupture of membranes (PROM)
2022-002480-30Phase 3Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dinoprostone in Rupture of amniotic membranes (PROM) and Pregnancy-related complication (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoints: Maternal and neonatal infectious morbidity and Need for neonatal respiratory support. Started Nov 2022; status: active.
02
Drugs
dinoprostone
03
Conditions
Rupture of amniotic membranes (PROM)Pregnancy-related complication
Beyond the preview
Go deeper on 2022-002480-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002480-30.